Hospital
Taylor County Hospital District Health Facilities Corporation
Taylor County Hospital District Health Facilities Corporation was paid $36.08M by Medicaid between Jan 2018 and Dec 2024, across 352 billing codes. Its largest line is 99283, emergency room visit (moderate) — 8.8% of everything it billed.
33Billing provider infoTAYLOR COUNTY HOSPITAL DISTRICT HEALTH FACILITIES CORPORATION
CAMPBELLSVILLE, KY 42718
CAMPBELLSVILLE, KY 42718
33aNPI1689761942assigned 10/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$36.08M
24GClaims1,136,604
24DCodes billed352
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#19 of 36
Median peer was paid$36.08M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 173,604 | $3.90M | |
| 2019 | 178,324 | $4.87M | |
| 2020 | 143,264 | $4.31M | |
| 2021 | 165,149 | $5.01M | |
| 2022 | 154,536 | $4.97M | |
| 2023 | 172,934 | $6.52M | |
| 2024incomplete | 148,793 | $6.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 28,262 | 24,649 | $3.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.7% | 15,957 | 13,531 | $2.43M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.5% | 1,519 | 1,325 | $1.61M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.0% | 5,059 | 3,669 | $1.08M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 3,490 | 2,587 | $1.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 6,139 | 3,975 | $895K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.3% | 25,685 | 22,197 | $818K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.3% | 10,708 | 9,325 | $812K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.1% | 850 | 784 | $752K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.0% | 1,252 | 1,200 | $706K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 10,328 | 5,362 | $684K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 11,272 | 7,417 | $661K |
340 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 11,445 | $622K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 9,096 | $609K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 14,979 | $554K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 13,036 | $544K |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 162,454 | $526K |
| 76830 | Ultrasound, transvaginal | 1.4% | 2,476 | $497K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 4,701 | $485K |
| 80053 | Comprehensive metabolic panel | 1.3% | 49,471 | $484K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 14,911 | $447K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 9,327 | $443K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 14,880 | $414K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.1% | 2,028 | $390K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 51,644 | $373K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 6,794 | $371K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 6,945 | $367K |
| 76801 | 1.0% | 2,339 | $362K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 10,875 | $344K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 943 | $339K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 374 | $325K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,781 | $322K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,537 | $309K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,534 | $300K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,524 | $290K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,755 | $288K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 766 | $279K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 929 | $274K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,218 | $264K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,177 | $262K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,008 | $250K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,778 | $240K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,024 | $233K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,271 | $225K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14,291 | $216K |
| 74178 | <1% | 460 | $200K | |
| 73630 | <1% | 3,777 | $199K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,021 | $182K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 362 | $180K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 461 | $176K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14,770 | $174K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,222 | $168K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 886 | $157K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 819 | $153K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,793 | $152K |
| 95811 | <1% | 206 | $148K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,860 | $146K |
| 73610 | <1% | 2,671 | $144K | |
| 87088 | <1% | 20,782 | $138K | |
| 83880 | <1% | 4,787 | $136K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,502 | $136K |
| 83735 | <1% | 21,804 | $131K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,367 | $121K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,751 | $121K |
| 80061 | Lipid panel | <1% | 9,852 | $118K |
| 73562 | <1% | 2,528 | $115K | |
| 87634 | <1% | 1,798 | $109K | |
| 73030 | <1% | 2,561 | $109K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,930 | $109K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,255 | $107K |
| 74018 | <1% | 2,293 | $103K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 12,129 | $101K |
| 84484 | <1% | 8,772 | $100K | |
| 72100 | <1% | 1,713 | $99K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,347 | $98K |
| 97161 | <1% | 1,987 | $97K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,882 | $96K |
| 99217 | <1% | 1,761 | $94K | |
| 96376 | <1% | 1,912 | $91K | |
| 73130 | <1% | 1,674 | $91K | |
| 80349 | <1% | 1,544 | $89K | |
| 85730 | <1% | 18,371 | $86K | |
| 87430 | <1% | 5,877 | $85K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 427 | $83K |
| 86922 | <1% | 2,572 | $82K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 173 | $79K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 222 | $78K |
| 76775 | <1% | 1,003 | $77K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,844 | $76K |
| 85610 | <1% | 20,526 | $76K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,290 | $74K |
| J0875 | Injection, dalbavancin, 5 mg | <1% | 25 | $74K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 509 | $72K |
| 82607 | <1% | 5,368 | $70K | |
| 20610 | <1% | 939 | $66K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,990 | $66K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,509 | $64K |
| 76536 | <1% | 352 | $61K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,651 | $60K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,857 | $59K |
| 81025 | <1% | 7,353 | $59K | |
| 84439 | <1% | 6,650 | $56K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 444 | $54K |
| 92557 | <1% | 1,036 | $54K | |
| 52000 | <1% | 232 | $54K | |
| 59025 | Fetal non-stress test | <1% | 650 | $54K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 807 | $53K |
| 81001 | <1% | 17,647 | $52K | |
| 93971 | <1% | 1,097 | $52K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,421 | $51K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,529 | $51K |
| 73110 | <1% | 923 | $50K | |
| 87186 | <1% | 5,809 | $50K | |
| 80305 | <1% | 4,295 | $49K | |
| 36600 | <1% | 2,422 | $49K | |
| 87040 | <1% | 4,069 | $47K | |
| 87081 | <1% | 6,253 | $47K | |
| 84702 | <1% | 3,211 | $45K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 97 | $45K |
| 82550 | <1% | 7,383 | $43K | |
| 82803 | <1% | 2,065 | $43K | |
| 99221 | <1% | 390 | $41K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,621 | $40K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 498 | $40K |
| 83690 | <1% | 6,028 | $39K | |
| 86703 | <1% | 2,394 | $39K | |
| 76642 | <1% | 674 | $38K | |
| 97010 | <1% | 4,909 | $36K | |
| 87070 | <1% | 3,966 | $34K | |
| 92579 | <1% | 525 | $33K | |
| 88304 | <1% | 918 | $33K | |
| 83605 | <1% | 3,125 | $33K | |
| 80320 | <1% | 2,268 | $33K | |
| 80324 | <1% | 1,145 | $33K | |
| 72040 | <1% | 706 | $32K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,000 | $31K |
| 81003 | <1% | 12,795 | $30K | |
| 92567 | <1% | 1,850 | $30K | |
| 96367 | <1% | 578 | $30K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,415 | $28K |
| 73560 | <1% | 890 | $28K | |
| 86803 | <1% | 1,887 | $28K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,373 | $26K |
| 82728 | <1% | 2,482 | $26K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,596 | $25K |
| 82150 | <1% | 4,335 | $25K | |
| 69210 | <1% | 961 | $25K | |
| 82746 | <1% | 1,746 | $22K | |
| 85379 | <1% | 2,391 | $22K | |
| 51798 | <1% | 875 | $22K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 187 | $22K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 4,600 | $21K |
| 80074 | <1% | 493 | $21K | |
| 85027 | <1% | 3,241 | $20K | |
| 80361 | <1% | 547 | $20K | |
| 73502 | <1% | 674 | $20K | |
| 82962 | <1% | 4,119 | $19K | |
| 86850 | <1% | 2,740 | $19K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 177 | $19K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 856 | $19K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 390 | $18K |
| 93017 | <1% | 139 | $18K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,473 | $18K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,478 | $18K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 492 | $17K |
| 87807 | <1% | 1,083 | $17K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,009 | $17K |
| 84703 | <1% | 2,192 | $17K | |
| 87653 | <1% | 518 | $16K | |
| 47562 | <1% | 14 | $16K | |
| 93970 | <1% | 181 | $16K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,326 | $16K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,363 | $15K |
| 82553 | <1% | 1,461 | $15K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,780 | $15K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 755 | $15K |
| 83540 | <1% | 2,505 | $14K | |
| 90715 | <1% | 449 | $13K | |
| 64425 | <1% | 227 | $13K | |
| 86762 | <1% | 1,264 | $13K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 811 | $12K |
| 72131 | <1% | 91 | $12K | |
| 87340 | <1% | 1,625 | $12K | |
| 97113 | <1% | 383 | $12K | |
| 71250 | <1% | 116 | $11K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 611 | $11K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,756 | $11K |
| 86140 | <1% | 2,250 | $11K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 86 | $11K |
| 87205 | <1% | 2,229 | $10K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,311 | $10K |
| 84403 | <1% | 421 | $10K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 746 | $10K |
| 76870 | <1% | 52 | $10K | |
| C1769 | Guide wire | <1% | 170 | $10K |
| 11043 | <1% | 49 | $10K | |
| 82043 | <1% | 1,967 | $10K | |
| 72141 | <1% | 24 | $9K | |
| 77080 | <1% | 326 | $9K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,092 | $9K |
| 70486 | <1% | 74 | $9K | |
| 73080 | <1% | 151 | $8K | |
| 84144 | <1% | 399 | $8K | |
| 82570 | <1% | 1,946 | $8K | |
| 86592 | <1% | 2,149 | $8K | |
| 84466 | <1% | 778 | $8K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 769 | $8K |
| 52332 | <1% | 13 | $8K | |
| J0558 | Injection, penicillin g benzathine and penicillin g procaine, 100,000 units | <1% | 66 | $7K |
| 83970 | <1% | 233 | $7K | |
| 83001 | <1% | 361 | $7K | |
| Q3014 | Telehealth originating site facility fee | <1% | 611 | $7K |
| 73590 | <1% | 139 | $7K | |
| 86769 | <1% | 244 | $7K | |
| 97162 | <1% | 117 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 24 | $7K |
| 86900 | <1% | 2,146 | $7K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,611 | $7K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 16 | $6K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 12 | $6K |
| 86901 | <1% | 2,140 | $6K | |
| 84550 | <1% | 1,401 | $6K | |
| 80348 | <1% | 233 | $6K | |
| 80347 | <1% | 177 | $6K | |
| 73221 | <1% | 12 | $5K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 1,092 | $5K |
| 96523 | <1% | 95 | $5K | |
| 80329 | <1% | 289 | $5K | |
| C1747 | Endoscope, single-use (i.e. disposable), urinary tract, imaging/illumination device (insertable) | <1% | 34 | $5K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 687 | $5K |
| 96401 | <1% | 52 | $5K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 135 | $4K |
| 93225 | <1% | 104 | $4K | |
| 77065 | Tomosynthesis, mammo | <1% | 52 | $4K |
| 94060 | <1% | 71 | $4K | |
| 73090 | <1% | 86 | $4K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 66 | $4K |
| 85018 | <1% | 938 | $4K | |
| 83550 | <1% | 1,308 | $4K | |
| 82950 | <1% | 774 | $4K | |
| 84436 | <1% | 745 | $4K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 175 | $4K |
| 0012A | <1% | 354 | $4K | |
| M0240 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses | <1% | 14 | $4K |
| 85652 | <1% | 1,534 | $4K | |
| 88312 | <1% | 151 | $3K | |
| 72072 | <1% | 71 | $3K | |
| 0011A | <1% | 323 | $3K | |
| 84153 | <1% | 229 | $3K | |
| 82565 | <1% | 268 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 790 | $3K |
| 73140 | <1% | 115 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 31 | $3K |
| 83721 | <1% | 1,005 | $3K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 62 | $3K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 19 | $3K |
| 73100 | <1% | 102 | $3K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $3K |
| 83002 | <1% | 153 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 26 | $3K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 41 | $3K |
| 85660 | <1% | 451 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 81 | $2K |
| 12001 | <1% | 25 | $2K | |
| 83615 | <1% | 450 | $2K | |
| 10060 | <1% | 48 | $2K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 198 | $2K |
| 96368 | <1% | 89 | $2K | |
| 86038 | <1% | 201 | $2K | |
| C9733 | Non-ophthalmic fluorescent vascular angiography | <1% | 14 | $2K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 184 | $2K |
| 86665 | <1% | 90 | $2K | |
| 92523 | <1% | 26 | $2K | |
| 93922 | <1% | 41 | $2K | |
| 84112 | <1% | 30 | $2K | |
| 85651 | <1% | 530 | $2K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 16 | $2K |
| 72110 | <1% | 33 | $2K | |
| 83525 | <1% | 189 | $2K | |
| 11721 | <1% | 168 | $2K | |
| 97165 | <1% | 50 | $2K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 750 | $2K |
| 84145 | <1% | 87 | $2K | |
| 82652 | <1% | 58 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 16 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 520 | $2K |
| 93880 | <1% | 12 | $2K | |
| 84481 | <1% | 126 | $2K | |
| 74022 | <1% | 27 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 794 | $2K |
| 86593 | <1% | 219 | $2K | |
| 87427 | <1% | 127 | $2K | |
| 86308 | <1% | 226 | $1K | |
| 93226 | <1% | 26 | $1K | |
| 84146 | <1% | 70 | $1K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 15 | $1K |
| 80076 | <1% | 176 | $1K | |
| 88104 | <1% | 74 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 407 | $1K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 145 | $1K |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 597 | $1K |
| 87045 | <1% | 111 | $1K | |
| 86664 | <1% | 50 | $959.00 | |
| 72170 | <1% | 35 | $945.02 | |
| 84156 | <1% | 352 | $932.13 | |
| 84479 | <1% | 165 | $851.05 | |
| 86663 | <1% | 50 | $822.73 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 103 | $819.55 |
| 83655 | <1% | 62 | $742.55 | |
| 82731 | <1% | 12 | $725.00 | |
| J3490 | Unclassified drugs | <1% | 72 | $697.74 |
| 82140 | <1% | 54 | $671.17 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 97 | $667.02 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 387 | $634.94 |
| 71101 | <1% | 14 | $630.36 | |
| 87324 | <1% | 61 | $629.65 | |
| 94729 | <1% | 15 | $622.67 | |
| 94727 | <1% | 15 | $603.41 | |
| 97597 | <1% | 22 | $601.23 | |
| 0013A | <1% | 61 | $595.35 | |
| 87046 | <1% | 67 | $589.09 | |
| 86757 | <1% | 28 | $577.36 | |
| 84207 | <1% | 27 | $513.66 | |
| 86618 | <1% | 29 | $511.82 | |
| 87449 | <1% | 40 | $491.57 | |
| 82670 | <1% | 12 | $388.00 | |
| 97014 | <1% | 34 | $382.53 | |
| 88342 | <1% | 13 | $346.56 | |
| 87522 | Neg quan hep c or qual rna | <1% | 14 | $327.93 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 33 | $311.28 |
| 97602 | <1% | 14 | $289.52 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 28 | $280.56 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 26 | $279.18 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 58 | $272.99 |
| 85008 | <1% | 416 | $262.11 | |
| 97164 | <1% | 12 | $246.00 | |
| 90633 | <1% | 12 | $243.11 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 5,266 | $228.59 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 15 | $225.74 |
| 86431 | <1% | 37 | $180.56 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 18 | $155.27 |
| 84425 | <1% | 12 | $151.99 | |
| 87177 | <1% | 15 | $151.00 | |
| 84100 | <1% | 29 | $106.71 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 20 | $100.39 |
| 82272 | <1% | 43 | $98.51 | |
| 87075 | <1% | 14 | $96.59 | |
| 90686 | <1% | 16 | $71.23 | |
| 82247 | <1% | 15 | $66.66 | |
| 85046 | <1% | 13 | $56.70 | |
| 84132 | <1% | 12 | $34.64 | |
| A9270 | Non-covered item or service | <1% | 107 | $5.90 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSABO, JR., JAMES (ACCOUNTS RECEIVABLE MANAGER)